-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network June 11 - The Office of the National Health and Health Commission issued a notice on June 9, requesting the collection of second- and third-level public hospitals in 2019 annual performance appraisal dataAll provincial health and health committees are required to complete the online audit of the data filled in by the tertiary public hospitals by June 26, and to complete the online audit of the data filled in by the second-level public hospitals by September 6.
Auxiliary drug monitoring covers the second-level hospital industry pay sorgas high-profile "auxiliary drug revenue ratio" indicators, this time in the "National Third-level Public Hospital Performance Assessment Operation Manual (2020 edition)" (hereinafter referred to as the "Third Hospital Manual"), to assess the first batch of state key monitoring of rational drug catalog (chemical drugs and biological products) published 20 drugs revenue as a proportion of total drug revenue (including emergency, hospitalization)However, the assessment indicators are still "monitoring comparison" rather than "gradual reduction".
However, it is worth noting that in the National Second Level Public Hospital Performance Assessment Operation Manual (2020) (hereinafter referred to as the "Second-level Hospital Manual"), although the formulation has been modified and no longer referred to as "auxiliary drug use", the focus on monitoring the proportion of drug revenue is still one of the assessment indicatorsIn other words, the state focuses on monitoring and monitoring the 20 drugs listed in the list of reasonable drugs and drugs, which officially covers medical institutions above the second level.
This change was actually expectedLast year issued "on the issuance of the first batch of state key monitoring of rational drug catalog (chemical drugs and biological products) notice" has clearly asked health and health administrative departments at all levels, Chinese medicine authorities and medical institutions to establish a sound clinical use of drugs monitoring and extraordinary early warning system, strengthen the clinical use of drugs monitoring and performance assessment, focusing on the clinical use of drugs included in the catalog as medical institutions and their principal stakes in the assessment contentAt the same time, medical institutions are required to establish a key monitoring and rational drug management system, and strengthen the catalog of drug clinical application of the whole management.
Analysts said that the focus on monitoring drug revenue ratio indicators included in the performance appraisal of secondary public hospitals, meaning that the relevant varieties in the second-level and above hospitals limited has been finalized.
The competitive pattern of the terminals of China's public medical institutions shows that the first batch of state key monitoring 20 varieties in 2018 in public hospitals terminal sales of 22.1 billion yuanAmong them, the first-in-the-forefront injection, injection of rat nerve growth factor, Idalafon injection and Changchun sitin injection and other four drugs in 2018 public hospital terminal sales of more than 3 billion yuan, involving 38 enterprisesHowever, last year in response to the "adjustment structure, Teng space, bao-linked" three medical linkage series of policies, medical insurance bidding departments and medical institutions around the country carried out a variety of control restrictions on the key monitoring of the list of drug use behavior, related products in public medical institutions basically did not grow, some have even seen a sharp decline.
(Source: Minne net medical insurance catalog library, MID drug index library, China's public medical institutions terminal competition pattern) the inclusion of the second and third-level public performance appraisal indicators, coupled with the 2019 version of the medical insurance catalog of the national key monitoring varieties were all transferred out, focusing on monitoring the future size of drugs is expected to be further compressed.
The importance of rational drug assessment increaseS In terms of medical institutions, in addition to auxiliary drug use, or focus on monitoring the proportion of drug revenue, including the proportion of prescriptions, antibacterial drug use intensity (DDDs), the proportion of prescriptions for essential drugs for outpatients, the proportion of basic drug purchases of inpatients, the proportion of basic drug purchase varieties and the proportion of national organizations in centralized drug procurement are included.
It is worth noting that the document clearly put forward that in order to make the relevant data comparable, the implementation of dynamic monitoring, in addition to special instructions, the quantitative indicatordata of this assessment on the basis of the past to increase the 2019 data, and requires all places should be in accordance with the principle of territorialization to strengthen data quality control, improve data quality, and constantly explore the use of data quality as a factor to adjust the results of the application mechanism The requirements for secondary hospitals are also clear, in addition to special instructions, the quantitative indicators required in this assessment are 2017-2019 data.
It is not difficult to foresee that with the accumulation of data over the years, intelligent analysis technology to improve, assessment data analysis application will be further strengthened, rational drug test results will be with medical institutions evaluation, evaluation more closely combined.
In addition, the three-level public hospital assessment indicators, but also added a key monitoring of high-value medical supplies revenue ratio of this indicator, requiring the assessment of the annual hospital focus on monitoring high-value medical supplies (i.e., the first batch of national high-value medical supplies key management list published 18 kinds of medical supplies) income accounted for the proportion of total income of consumables in the same period This is based on the "State Council General Office on the issuance of high-value medical supplies reform program notice" and added one, the goal is to comprehensively and deeply control high-value medical supplies, regulate medical services behavior, control unreasonable growth of medical costs.